ArticleCancer research communications2026
Identification of a Two-Gene Biomarker Correlated with Sensitivity to Combined PARP7 Inhibition and AHR Activation in Cancer Cells.
Article in Cancer research communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
PARP7 inhibitors (PARP7i) and aryl hydrocarbon receptor agonists (AHRa) can synergistically suppress growth of some cancer cell lines but not others. In this study, we derived a two-gene transcriptional score to predict the synergistic response and characterized the molecular, immune, and prognostic features of this biomarker. Cancer cells were categorized into synergistic and nonsynergistic cell lines based on synergy scores that we previously reported. Published RNA sequencing data were used to establish a biomarker for PARP7i and AHRa synergistic response that was comprised of the expression of the two most differentially expressed immune-related genes (CCL22 and TNFSF10). This biomarker was successfully validated in an independent set of cell lines. An integrated multiomics analysis revealed that synergistic lines had increased expression of immune-related gene sets and low expression of epithelial-mesenchymal transition-associated genes and co-expression network analysis identified transcription factors associated with synergy. In The Cancer Genome Atlas patients with breast and prostate cancers, biomarker genes were correlated with immune cell infiltration. Receiver operator characteristic (ROC) and hazard ratio (HR) analyses demonstrated that the biomarker score was correlated with response to anti-programmed cell death protein 1 (PD-1) therapy in a cohort of patients with kidney cancer and correlated with better overall survival in patients with cancer treated with anti-programmed cell death ligand 1 (PD-L1) and anti-cytotoxic T-lymphocyte-associated protein 4 therapies. In summary, we have identified a transcriptional biomarker that predicts cellular response to PARP7i and AHRa combination therapy, which is associated with benefits from immune checkpoint inhibitor therapies in patients with cancer. SIGNIFICANCE: We employed a multiomic approach to identify a transcriptional biomarker that is predictive of cellular response to combined treatment with PARP7i and AHRa. The molecular, immune, and prognostic characterizations of this biomarker may provide insights into the molecular mechanisms of response and aid in stratifying patients likely to benefit from this combination therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.